Interventions of Interest: Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year. At the January 20 virtual meeting, ICER’s independent appraisal committee will review the evidence, […]
Intervention of interest: Diabetes prevention programs The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus each year. The direct medical costs of diabetes were estimated to be $176 billion in 2012. Interventions to prevent diabetes have the potential to save […]
Interventions of Interest: oral semaglutide (Rybelsus®, Novo Nordisk) liraglutide (Victoza®, Novo Nordisk) sitagliptin (Januvia®, Merck) empagliflozin (Jardiance®, Boehringer Ingelheim). Type 2 diabetes mellitus (T2DM) is a condition where cells do not respond adequately to insulin and so there are high glucose (sugar) levels. In the United States approximately 30 million individuals have diabetes mellitus (DM), […]
2014 Interventions of Interest: Sulfonylureas Insulin Dipeptidyl peptidase-4 (DPP-4) inhibitors Glucagon-like peptide-1 (GLP-1) receptor agonists Continuous blood glucose monitoring The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have […]
Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S). The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control […]